summaryrefslogtreecommitdiff
path: root/2026/08/25/非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界/index.html
diff options
context:
space:
mode:
authori-shm <[email protected]>2026-08-24 17:06:21 +0000
committeri-shm <[email protected]>2026-08-24 17:06:21 +0000
commit0205e19c79843662937fb6fbab4df74de99723bd (patch)
tree2f7d233b467309fcbcfaa2f11b3d60a236880c27 /2026/08/25/非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界/index.html
parentd4d86a44cca659a546878115fda05345c1c0a41d (diff)
downloadblog-0205e19c79843662937fb6fbab4df74de99723bd.tar.gz
deploy: 9f1634858e06157665154ea9faa541e2e16b31f7
Diffstat (limited to '2026/08/25/非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界/index.html')
-rw-r--r--2026/08/25/非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界/index.html365
1 files changed, 365 insertions, 0 deletions
diff --git a/2026/08/25/非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界/index.html b/2026/08/25/非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界/index.html
new file mode 100644
index 00000000..b7b85652
--- /dev/null
+++ b/2026/08/25/非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界/index.html
@@ -0,0 +1,365 @@
+<!DOCTYPE html>
+<html lang="en">
+ <head>
+ <meta charset="UTF-8">
+<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0">
+<meta http-equiv="X-UA-Compatible" content="ie=edge">
+
+ <meta name="author" content="韩暮秋">
+
+
+ <meta name="subtitle" content="暮秋小屋">
+
+
+ <meta name="description" content="这里是暮秋小屋,思念和灵感的寄存处">
+
+
+ <meta name="keywords" content="韩暮秋,MuqiuHan,'Muqiu Han', 'muqiu han', muqiuhan">
+
+
+
+
+ <title>
+
+ 非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界 |
+ 暮秋小屋
+ </title>
+
+
+
+ <link rel="icon" href="/favicon.ico">
+
+
+
+
+ <!-- stylesheets list from _config.yml -->
+
+ <link rel="stylesheet" href="/css/style.css">
+
+
+
+
+ <link rel="preload" href="/fonts/FZYouSongS-509R.woff2" as="font" type="font/woff2" crossorigin>
+
+
+
+ <!-- scripts list from _config.yml -->
+
+ <script
+ src="/js/menu.js"></script>
+
+
+
+
+
+ <script
+ src="https://polyfill.alicdn.com/polyfill.js?features=es6"></script>
+ <script
+ id="MathJax-script"
+ async
+ src="https://lf6-cdn-tos.bytecdntp.com/cdn/expire-1-M/mathjax/3.2.0/es5/tex-mml-chtml.js"></script>
+
+
+
+
+ <meta name="generator" content="Hexo 6.3.0"></head>
+ <body>
+ <div class="wrapper">
+
+ <div class="header">
+ <div class="flex-container">
+ <div class="header-inner">
+ <div class="site-brand-container">
+ <a href="/">
+
+ 暮秋小屋
+
+ </a>
+ </div>
+ <div id="menu-btn" class="menu-btn" onclick="toggleMenu()">
+ 菜单
+ </div>
+ <nav class="site-nav">
+ <ul class="menu-list">
+
+
+ <li class="menu-item">
+ <a href="/">
+ 主页
+ </a>
+ </li>
+
+
+
+ <li class="menu-item">
+ <a href="/categories/gallery/">
+ 日记本
+ </a>
+ </li>
+
+
+
+ <li class="menu-item">
+ <a href="/tags/Medicine/">
+ 泛医学
+ </a>
+ </li>
+
+
+
+ <li class="menu-item">
+ <a href="/tags/Technique/">
+ 计算机
+ </a>
+ </li>
+
+
+
+ <li class="menu-item">
+ <a href="/tags/Life/">
+ 生活
+ </a>
+ </li>
+
+
+
+ <li class="menu-item">
+ <a href="/archives">
+ 全部
+ </a>
+ </li>
+
+
+
+ <li class="menu-item">
+ <a href="/about">
+ 关于
+ </a>
+ </li>
+
+
+
+ <li class="menu-item">
+ <a href="/search">搜索</a>
+ </li>
+
+ </ul>
+ </nav>
+ </div>
+ </div>
+</div>
+
+
+ <div class="main">
+ <div class="flex-container">
+ <article id="post">
+
+
+ <div class="post-head">
+ <div class="post-info">
+ <div class="tag-list">
+
+
+ <span class="post-tag">
+ <a href="/tags/Medicine/">
+ Medicine
+ </a>
+ </span>
+
+
+ </div>
+ <div class="post-title">
+
+
+ 非小细胞肺癌鳞状分化的免疫组化判读及其治疗边界
+
+
+ </div>
+ <span class="post-date">
+ Aug 25, 2026
+ </span>
+ </div>
+ <div class="post-img">
+
+ <div class="h-line-primary"></div>
+
+ </div>
+</div>
+ <div class="post-content">
+ <p>一份常见的病理附文会把 P40 阳性、CK5/6 阳性、CK7 阴性和 P53 弥漫强阳、HER2 评 0 写成闭环:定型为纯肺鳞癌,排除腺癌与腺鳞癌,证明吸烟致癌,并宣布不必等待驱动基因、直接进入免疫联合化疗。P40 对鳞状分化的证据成立。后半段把互不矛盾当成互为证明,治疗推断超出了这四张片子能回答的问题。</p>
+<p>低分化非小细胞肺癌需要免疫组化分型,首选组合是 TTF-1 加 P40。鳞癌不用培美曲塞,也不用贝伐珠单抗。IHC 验证的纯鳞癌在长期重度吸烟者中 EGFR、ALK 极罕见。这些是共识。闭环叙事多走了三步:用 CK7 排除腺鳞癌,用 P53 挑选免疫治疗人群,用 HER2 IHC 0 关闭德曲妥珠单抗。</p>
+<h2 id="P40-回答的是当前切片有没有鳞状分化"><a class="header-anchor" href="#P40-回答的是当前切片有没有鳞状分化">¶</a>P40 回答的是当前切片有没有鳞状分化</h2>
+<p>P40 识别 p63 的 ΔNp63 异构体。ΔNp63 在复层上皮基底细胞维持增殖潜能,不携带 TAp63 那种更广谱的交叉反应。Bishop 等在 81 例肺鳞癌、237 例腺癌和 152 例大细胞淋巴瘤中比较 4A4(同时识别 TA 与 ΔN)与 P40:两者在鳞癌均阳性,平均阳性细胞比例 97% 对 96%;P63 标出 31% 腺癌和 54% 大细胞淋巴瘤,特异度 60%;P40 只标出 3% 腺癌,且阳性细胞不超过 5%,淋巴瘤全阴,特异度 98%。<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup> Nonaka 在 150 例腺癌中 P40 全阴,50 例鳞癌两者均弥漫阳性。<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup> Kriegsmann 等 1244 例里,CK5/6、P40、P63 对鳞癌的敏感度是 93%、94%、94%,特异度是 98%、97%、84%。<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup></p>
+<p>“特异度接近 100%、敏感度约 95%”方向对,数字被圆滑了。Affandi 等小样本中 P40 在原发肺鳞癌的敏感度只有 77.1%。<sup class="footnote-ref"><a href="#fn4" id="fnref4">[4]</a></sup> IASLC 病理委员会 2019 年最佳实践把 TTF-1 加 P40 定为日常标准组合,并建议 P40 以超过 50% 肿瘤细胞核阳性为切点;局灶 TTF-1 在合适临床背景下仍支持腺癌。<sup class="footnote-ref"><a href="#fn5" id="fnref5">[5]</a></sup> CK5/6 是高分子量角蛋白,标的是细胞骨架。Rekhtman 等 315 例全切片显示,鳞癌表型高度一致,腺癌却有 32% P63、18% CK5/6 阳性。一线够用的是 TTF-1 与鳞状核标志,CK5/6 只处理少数不定病例。<sup class="footnote-ref"><a href="#fn6" id="fnref6">[6]</a></sup></p>
+<p>P40 与 CK5/6 同步强阳不能写成 100% 纯鳞谱系,也不能排除低分化腺癌、大细胞癌和大细胞神经内分泌癌。Kadota 等把 480 例原诊鳞癌的切除标本用 P40 和 TTF-1 重读,4.2% 改判腺癌,其余还有腺鳞癌、大细胞癌、大细胞神经内分泌癌和小细胞癌。<sup class="footnote-ref"><a href="#fn7" id="fnref7">[7]</a></sup> 同一肿瘤细胞共表达 TTF-1 与 P40 的双表型癌已有报道。<sup class="footnote-ref"><a href="#fn8" id="fnref8">[8]</a></sup> 神经内分泌癌的排除依赖形态加 INSM1 或突触素,这两张片子完不成这项工作。</p>
+<h2 id="CK7-阴不能排除腺癌,更不能排除腺鳞癌"><a class="header-anchor" href="#CK7-阴不能排除腺癌,更不能排除腺鳞癌">¶</a>CK7 阴不能排除腺癌,更不能排除腺鳞癌</h2>
+<p>CK7 是低分子量角蛋白,广泛存在于腺上皮、导管和部分鳞状上皮。肺腺癌 CK7 阳性率很高,IASLC 仍明确写了:不要用 CK7 区分肺腺癌与鳞癌;单 CK7 阳、TTF-1 与 P40 都阴,仍应诊断为 NSCC NOS。<sup class="footnote-ref"><a href="#fn5" id="fnref5:1">[5:1]</a></sup> Zhao 等正因为 CK7 特异度低,把它移出活检推荐组合,留下 P40、CK5/6、TTF-1 和 Napsin A。<sup class="footnote-ref"><a href="#fn9" id="fnref9">[9]</a></sup></p>
+<p>腺鳞癌的定义是同一肿瘤里腺癌与鳞癌成分各自至少约 10%,原则上要看切除标本。活检只看到鳞癌区 P40 阳、CK5/6 阳、CK7 阴,证明不了未取样区没有腺癌。Shu 等报告肺腺鳞癌 EGFR 突变 11%、KRAS 突变 33%,微切割后突变在两种成分里收敛;胸苷酸合成酶表达更接近鳞癌。<sup class="footnote-ref"><a href="#fn10" id="fnref10">[10]</a></sup> Rekhtman 等复盘 16 例“鳞癌却有 EGFR 或 KRAS 突变”:63% 是腺鳞癌,31% 是形态学模仿鳞癌的低分化腺癌。<sup class="footnote-ref"><a href="#fn11" id="fnref11">[11]</a></sup></p>
+<p>CK7 阴性只说明当前切片这个区域符合鳞状表型。把它写成彻底排除腺癌以及腺鳞癌,是整条叙事里最大的方法学错误。</p>
+<h2 id="P53-弥漫强阳在肺鳞癌里是背景"><a class="header-anchor" href="#P53-弥漫强阳在肺鳞癌里是背景">¶</a>P53 弥漫强阳在肺鳞癌里是背景</h2>
+<p>野生型 p53 半衰期短,免疫组化呈斑驳核着色。错义突变常使蛋白稳定堆积,变成弥漫均一强核着色;截短或缺失突变则完全空白。Köbel 等在卵巢癌把过表达、完全缺失、胞质型和野生型与测序对上,过表达对应错义突变。<sup class="footnote-ref"><a href="#fn12" id="fnref12">[12]</a></sup> 这套判读来自妇科病理,不是肺鳞癌的注册级伴生诊断。90% 以上强阳支持突变型着色,不等于已经完成 TP53 测序。</p>
+<p>吸烟与 TP53 的关系要靠突变谱。Le Calvez 等:从不、既往、当前吸烟者的突变率分别是 47.5%、55.6%、77.4%,G 到 T 颠换与当前吸烟相关。<sup class="footnote-ref"><a href="#fn13" id="fnref13">[13]</a></sup> 苯并芘造成的 G 到 T 是测序指纹,免疫组化读不出来。TCGA 178 例肺鳞癌中 TP53 几乎见于全部标本,同时还高频累及 NFE2L2/KEAP1、PI3K 通路和 CDKN2A/RB1。<sup class="footnote-ref"><a href="#fn14" id="fnref14">[14]</a></sup> 在肺鳞癌里,P53 突变型着色的先验概率极高,不能把患者从普通鳞癌里挑出来。</p>
+<p>把几乎全员阳性的事件当成免疫治疗选择因子,逻辑不成立。转移性鳞癌一线获益来自 KEYNOTE-407:帕博利珠单抗联合卡铂加紫杉醇或白蛋白紫杉醇,中位总生存 15.9 对 11.3 个月,风险比 0.64,且不依赖 PD-L1 分层。<sup class="footnote-ref"><a href="#fn15" id="fnref15">[15]</a></sup> 可手术患者的证据是 CheckMate 816、AEGEAN 和 KEYNOTE-671。<sup class="footnote-ref"><a href="#fn16" id="fnref16">[16]</a></sup><sup class="footnote-ref"><a href="#fn17" id="fnref17">[17]</a></sup><sup class="footnote-ref"><a href="#fn18" id="fnref18">[18]</a></sup> 这些试验的入组轴是组织学加 PD-L1,不是 P53。</p>
+<h2 id="HER2-评-0-关掉的是过表达,不是突变"><a class="header-anchor" href="#HER2-评-0-关掉的是过表达,不是突变">¶</a>HER2 评 0 关掉的是过表达,不是突变</h2>
+<p>肺癌 HER2 改变分突变、扩增和过表达,三者不完全重叠。Mazières 等报告 HER2 突变约占非小细胞肺癌的 1% 到 2%,几乎都在腺癌,从不吸烟者更多见。<sup class="footnote-ref"><a href="#fn19" id="fnref19">[19]</a></sup> 肺癌里德曲妥珠单抗的注册路径是 HER2 突变。DESTINY-Lung01 突变队列客观缓解率 55%,检测不到 HER2 蛋白或没有扩增的患者也有缓解。<sup class="footnote-ref"><a href="#fn20" id="fnref20">[20]</a></sup> DESTINY-Lung02 在 5.4 mg/kg 剂量的确认缓解率是 49.0%。<sup class="footnote-ref"><a href="#fn21" id="fnref21">[21]</a></sup> 过表达队列(免疫组化 2+ 或 3+、无已知突变)缓解率只有 26.5% 到 34.1%,且入组是非鳞癌。<sup class="footnote-ref"><a href="#fn22" id="fnref22">[22]</a></sup> 吡咯替尼针对的也是突变或 20 外显子插入。</p>
+<p>HER2 评 0 的正确读法:当前切片没有膜过表达。它不能证明不适用德曲妥珠单抗,也不能用来印证典型吸烟相关纯鳞癌。</p>
+<div class="nsclc-ihc-map">
+<style>
+.nsclc-ihc-map{margin:1.4em 0 1.6em;max-width:100%;overflow-x:auto}
+.nsclc-ihc-map svg{display:block;width:100%;height:auto;max-width:720px;margin:0 auto}
+.nsclc-ihc-map .cap{font-size:0.85em;color:#555;margin:0.4em 0 0}
+</style>
+<svg viewBox="0 0 720 280" role="img" aria-label="四项免疫组化各自回答的问题">
+<rect x="0.5" y="0.5" width="719" height="279" fill="#f7f4ee" stroke="#c8c2b4"/>
+<text x="24" y="28" fill="#222" font-size="14" font-family="serif">教学示意:四项标记各自回答什么</text>
+<rect x="24" y="48" width="150" height="64" fill="#fff" stroke="#333"/>
+<text x="99" y="74" text-anchor="middle" font-size="13" fill="#111" font-family="serif">P40 ± TTF-1</text>
+<text x="99" y="94" text-anchor="middle" font-size="11" fill="#444" font-family="serif">当前切片的分化</text>
+<rect x="198" y="48" width="150" height="64" fill="#fff" stroke="#333"/>
+<text x="273" y="74" text-anchor="middle" font-size="13" fill="#111" font-family="serif">CK5/6</text>
+<text x="273" y="94" text-anchor="middle" font-size="11" fill="#444" font-family="serif">少数不定病例的仲裁</text>
+<rect x="372" y="48" width="150" height="64" fill="#fff" stroke="#333"/>
+<text x="447" y="74" text-anchor="middle" font-size="13" fill="#111" font-family="serif">CK7</text>
+<text x="447" y="94" text-anchor="middle" font-size="11" fill="#444" font-family="serif">角蛋白谱,不分型</text>
+<rect x="546" y="48" width="150" height="64" fill="#fff" stroke="#333"/>
+<text x="621" y="74" text-anchor="middle" font-size="13" fill="#111" font-family="serif">P53 / HER2 IHC</text>
+<text x="621" y="94" text-anchor="middle" font-size="11" fill="#444" font-family="serif">背景或过表达,不选药</text>
+<line x1="360" y1="128" x2="360" y2="152" stroke="#333"/>
+<rect x="150" y="152" width="420" height="96" fill="#fff" stroke="#333"/>
+<text x="360" y="178" text-anchor="middle" font-size="13" fill="#111" font-family="serif">鳞状分化成立之后</text>
+<text x="360" y="200" text-anchor="middle" font-size="12" fill="#333" font-family="serif">避开培美曲塞与贝伐珠单抗</text>
+<text x="360" y="220" text-anchor="middle" font-size="12" fill="#333" font-family="serif">仍做 PD-L1;按吸烟史、年龄、标本类型决定 NGS</text>
+<text x="360" y="238" text-anchor="middle" font-size="11" fill="#666" font-family="serif">示意图仅用于说明标记分工,不能替代个体病理诊断</text>
+</svg>
+<p class="cap">图 1 教学示意。P40 加 TTF-1 完成分型;其余三项不构成治疗闭环。</p>
+</div>
+<h2 id="四项齐了仍回答不了的治疗问题"><a class="header-anchor" href="#四项齐了仍回答不了的治疗问题">¶</a>四项齐了仍回答不了的治疗问题</h2>
+<p>培美曲塞在鳞癌疗效差是 III 期事实。Scagliotti 等 1725 例:腺癌中顺铂联合培美曲塞总生存 12.6 对 10.9 个月,鳞癌中吉西他滨更好,10.8 对 9.4 个月。<sup class="footnote-ref"><a href="#fn23" id="fnref23">[23]</a></sup> 机制侧写是鳞癌胸苷酸合成酶更高。Tanaka 等 2621 例:原发灶 TS/β-actin 均值腺癌 2.3、鳞癌 4.3。<sup class="footnote-ref"><a href="#fn24" id="fnref24">[24]</a></sup></p>
+<p>贝伐珠单抗的出血风险真实。Johnson 等 II 期把大咯血与鳞癌组织学、坏死空洞、邻近大血管联系起来,随后的 III 期因此排除鳞癌。<sup class="footnote-ref"><a href="#fn25" id="fnref25">[25]</a></sup> Sandler 等在非鳞癌中看到总生存 12.3 对 10.3 个月,有临床意义的出血 4.4% 对 0.7%。<sup class="footnote-ref"><a href="#fn26" id="fnref26">[26]</a></sup> “鳞癌不用贝伐珠单抗”作为规则成立。把它全部归因于肺门中央、容易空洞,是简化。</p>
+<p>“纯鳞癌不必优先查 EGFR、ALK”只在窄条件成立:切除标本、免疫组化验证的纯鳞癌、长期重度吸烟。Rekhtman 等 95 例 ΔNp63 阳、TTF-1 阴的鳞癌中 EGFR 与 KRAS 为 0,95% 置信区间 0 到 3.8%。<sup class="footnote-ref"><a href="#fn11" id="fnref11:1">[11:1]</a></sup> CAP、IASLC 与 AMP 2018 年指南更谨慎:非腺癌在年轻、少烟或从不吸烟、或标本可能漏掉腺癌成分时,仍可做分子检测。<sup class="footnote-ref"><a href="#fn27" id="fnref27">[27]</a></sup> 中国 NGS 共识同样:单纯肺鳞癌不常规查 EGFR;小标本诊断的鳞癌、混合腺癌成分、年轻或不吸烟者仍建议检测。<sup class="footnote-ref"><a href="#fn28" id="fnref28">[28]</a></sup></p>
+<p>把转移瘤一线和可手术围手术期揉在一起,再把吉西他滨写成与 KEYNOTE-407 同等的免疫联合伙伴,证据对不上。有 III 期数据的转移性鳞癌一线是帕博利珠单抗联合卡铂加紫杉醇或白蛋白紫杉醇。吉西他滨铂类是化疗时代的鳞癌方案。组织要留给分子检测和 PD-L1,而不是再加 CK7、P53、HER2 去闭合一条叙事。</p>
+<h2 id="读法"><a class="header-anchor" href="#读法">¶</a>读法</h2>
+<p>P40 阳、TTF-1 阴,CK5/6 可作支持:当前标本支持鳞状分化,化疗避开培美曲塞和贝伐珠单抗。下一步仍是分期、PD-L1,以及按吸烟史、年龄、标本类型决定要不要广谱 NGS。P53 弥漫强阳只是与鳞癌基因组背景相容。HER2 评 0 关掉过表达通路,不是突变通路。四项齐了,不等于诊断闭环,更不等于可以宣布不必等待靶向基因。</p>
+<hr>
+<h2 id="参考资料"><a class="header-anchor" href="#参考资料">¶</a>参考资料</h2>
+<hr class="footnotes-sep">
+<section class="footnotes">
+<ol class="footnotes-list">
+<li id="fn1" class="footnote-item"><p>Bishop JA, et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. <em>Mod Pathol</em>. 2012. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/22056955/">PMID: 22056955</a> <a href="#fnref1" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn2" class="footnote-item"><p>Nonaka D. A study of ΔNp63 expression in lung non-small cell carcinomas. <em>Am J Surg Pathol</em>. 2012. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/22367298/">PMID: 22367298</a> <a href="#fnref2" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn3" class="footnote-item"><p>Kriegsmann K, et al. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer. <em>Pathology</em>. 2019. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/30798982/">PMID: 30798982</a> <a href="#fnref3" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn4" class="footnote-item"><p>Affandi KA, et al. p40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma. <em>J Pathol Transl Med</em>. 2018. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/30235512/">PMID: 30235512</a> <a href="#fnref4" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn5" class="footnote-item"><p>Yatabe Y, et al. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <em>J Thorac Oncol</em>. 2019. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/30572031/">PMID: 30572031</a> <a href="#fnref5" class="footnote-backref">↩︎</a> <a href="#fnref5:1" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn6" class="footnote-item"><p>Rekhtman N, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma. <em>Mod Pathol</em>. 2011. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/21623384/">PMID: 21623384</a> <a href="#fnref6" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn7" class="footnote-item"><p>Kadota K, et al. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma. <em>Am J Surg Pathol</em>. 2015. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/25871623/">PMID: 25871623</a> <a href="#fnref7" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn8" class="footnote-item"><p>Pelosi G, et al. Challenging lung carcinoma with coexistent ΔNp63/p40 and TTF-1 labeling within the same individual tumor cells. <em>J Thorac Oncol</em>. 2015. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/26398824/">PMID: 26398824</a> <a href="#fnref8" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn9" class="footnote-item"><p>Zhao W, et al. ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. <em>Int J Clin Exp Pathol</em>. 2014. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/25120805/">PMID: 25120805</a> <a href="#fnref9" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn10" class="footnote-item"><p>Shu C, et al. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. <em>Mod Pathol</em>. 2013. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/22996376/">PMID: 22996376</a> <a href="#fnref10" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn11" class="footnote-item"><p>Rekhtman N, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung. <em>Clin Cancer Res</em>. 2012. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/22228640/">PMID: 22228640</a> <a href="#fnref11" class="footnote-backref">↩︎</a> <a href="#fnref11:1" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn12" class="footnote-item"><p>Köbel M, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. <em>J Pathol Clin Res</em>. 2016. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/27840695/">PMID: 27840695</a> <a href="#fnref12" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn13" class="footnote-item"><p>Le Calvez F, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke. <em>Cancer Res</em>. 2005. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/15958551/">PMID: 15958551</a> <a href="#fnref13" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn14" class="footnote-item"><p>Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. <em>Nature</em>. 2012. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/22960745/">PMID: 22960745</a> <a href="#fnref14" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn15" class="footnote-item"><p>Paz-Ares L, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. <em>N Engl J Med</em>. 2018. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/30280635/">PMID: 30280635</a> <a href="#fnref15" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn16" class="footnote-item"><p>Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <em>N Engl J Med</em>. 2022. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/35403841/">PMID: 35403841</a> <a href="#fnref16" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn17" class="footnote-item"><p>Heymach JV, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. <em>N Engl J Med</em>. 2023. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/37870974/">PMID: 37870974</a> <a href="#fnref17" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn18" class="footnote-item"><p>Wakelee H, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. <em>N Engl J Med</em>. 2023. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/37272513/">PMID: 37272513</a> <a href="#fnref18" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn19" class="footnote-item"><p>Mazières J, et al. Lung cancer that harbors an HER2 mutation. <em>J Clin Oncol</em>. 2013. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/23610105/">PMID: 23610105</a> <a href="#fnref19" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn20" class="footnote-item"><p>Li BT, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. <em>N Engl J Med</em>. 2022. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/34534430/">PMID: 34534430</a> <a href="#fnref20" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn21" class="footnote-item"><p>Goto K, et al. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: DESTINY-Lung02. <em>J Clin Oncol</em>. 2023. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/37694347/">PMID: 37694347</a> <a href="#fnref21" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn22" class="footnote-item"><p>Smit EF, et al. Trastuzumab deruxtecan in patients with metastatic NSCLC: DESTINY-Lung01 HER2-overexpressing cohorts. <em>Lancet Oncol</em>. 2024. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/38547891/">PMID: 38547891</a> <a href="#fnref22" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn23" class="footnote-item"><p>Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed. <em>J Clin Oncol</em>. 2008. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/18506025/">PMID: 18506025</a> <a href="#fnref23" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn24" class="footnote-item"><p>Tanaka F, et al. Thymidylate synthase gene expression in primary lung cancer patients. <em>Ann Oncol</em>. 2011. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/21321092/">PMID: 21321092</a> <a href="#fnref24" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn25" class="footnote-item"><p>Johnson DH, et al. Randomized phase II trial of bevacizumab plus carboplatin and paclitaxel. <em>J Clin Oncol</em>. 2004. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/15169807/">PMID: 15169807</a> <a href="#fnref25" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn26" class="footnote-item"><p>Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. <em>N Engl J Med</em>. 2006. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/17167137/">PMID: 17167137</a> <a href="#fnref26" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn27" class="footnote-item"><p>Lindeman NI, et al. Updated Molecular Testing Guideline. <em>Arch Pathol Lab Med</em>. 2018. <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/29355391/">PMID: 29355391</a> <a href="#fnref27" class="footnote-backref">↩︎</a></p>
+</li>
+<li id="fn28" class="footnote-item"><p>二代测序技术在 NSCLC 中的临床应用中国专家共识(2020 版). <a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519957/">PMC7519957</a> <a href="#fnref28" class="footnote-backref">↩︎</a></p>
+</li>
+</ol>
+</section>
+
+</div>
+
+<script>
+ window.onload = detectors();
+</script>
+ <div class="post-footer">
+ <div class="h-line-primary"></div>
+ <nav class="post-nav">
+ <div class="prev-item">
+
+ </div>
+ <div class="next-item">
+
+ <div class="icon arrow-right"></div>
+ <div class="post-link">
+ <a href="/2026/08/25/%E9%BB%84%E9%87%91%E5%AE%9A%E4%BB%B7%E4%B8%8E%E5%A2%83%E5%86%85%E6%8A%95%E8%B5%84%E9%80%9A%E8%B7%AF/">Next</a>
+ </div>
+
+ </div>
+ </nav>
+</div>
+
+
+ <div class="post-comment">
+
+
+
+
+
+
+
+</div>
+
+
+</article>
+ </div>
+ </div>
+
+ <div class="footer">
+ <div class="flex-container">
+ <div class="footer-text">
+
+
+ 韩暮秋 |
+
+
+ 希望路过的人可以添点柴火让这里暖和点
+
+ </div>
+ </div>
+</div>
+
+
+ </div>
+
+ <script src="/js/mermaid-zoom.js"></script>
+
+ </body>
+</html>